Antitumor necrosis factor therapy for adult Crohn's disease;Traitement de la maladie de Crohn de l'adulte par anticorps anti-tumor necrosis factor-α (TNFα)

Revue Medicale de Liege

Volumn 55, Issue 9, 2000, Pages 827-832

  Belaiche, J ^a   Louis, E ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Anti TNF ; Crohn's disease; Infliximab

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; INFECTION; LYMPHOMA; REMISSION; RETREATMENT; REVIEW; TOXICITY;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033760745     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Corticosteroid treatment in active Crohn's disease
2. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
3. Infliximab: A novel chimeric monoclonal antibody for the treatment of crohn's disease
4. Review article: Targeting TNFα as a key cytokine in the inflammatory processes of Crohn's disease - The mechanisms of action of infliximab
5. A high serum concentration of interleukin,-6 is predictive of relapse in quiescent Crohn's disease
6. Increased production of matrix metalloproteinase-3 and tissue of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease
7. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease
8. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease
9. Infliximab a chimeric TNFα antibody downregulates INF-γ production in gut derived T lymphocytes from patients with Crohn's disease
10. Increased peripheral production of TNFα and mucosal levels of activated NFkB predict relapse after treatment with infliximab in patients with Crohn's disease
11. Tumor-necrosis-factor antibody treatment in Crohn's disease
12. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
13. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
14. Confirmed response rates to infliximab treatment for refractory and fistulizing Crohn's disease in a Belgian expanded access program
15. Consistent treatment benefit with infliximab in patients with moderate-to-severe active Crohn's disease
16. Endoscopic and histological healing with antitumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
17. Tumor necrosis factor α antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis
18. Infliximab (anti-TNF-antibody) induces histological remission without increase of epithelial cell proloferation
19. Longer remission of Crohn's disease with infliximab related to AZA/6MP-use and multiple infusions
20. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
21. Infliximab for the treatment of fistulas in patients with Crohn's disease
22. Consistent treatment benefit with infliximab in patients with fistulizing Crohn's disease
23. Treatment of therapy-resistant perineal metastatic Crohn's disease after protectomy using anti-tumor necrosis chimeric monoclonal antibody, cA2
24. Successful management of Crohn's disease of the ileoanal pouch with infliximab
25. A randomized, double-blind, placebo-controlled, multicenter-trial of the engineered human antibody to TNF (CDP571) for steroid soaring and maintenance of remission in patients with steroid-dependent Crohn's disease
26. Review article: Safety of infliximab in clinical trials
27. Delayed hypersensitivity to infliximab (Remicade(®)) re-infusion after a 2-4 year interval without treatment
28. The relationship between infliximab treatment and lymphoma in Crohn's disease